Atrium Therapeutics Inc (RNA)

EBITDA Margin

-404.56%

TTM · Period ending:

RNA logo

RNA EBITDA Margin

Latest reported-404.56%
RNA TTM EBITDA Margin (-404.56% → -404.56%)
More history is needed to export this chart.

RNA ebitda margin history

Trailing twelve months (TTM). Each value covers four complete reported quarters.

Atrium Therapeutics Inc EBITDA Margin — Trailing twelve months (TTM)
Period endingEBITDA Margin
-404.5621%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.